Paediatric Clinical Neurology
Basic and Clinical Pharmacology, 11th Edition
The most trusted and up-to-date pharmacology text in medicine — completely redesigned to make the learning process even more interesting and efficient
A Doody’s Core Title ESSENTIAL PURCHASE for 2011!
5 Star Doody’s Review!
“This is the most widely used textbook for teaching pharmacology to health professionals. This 11th edition is far superior to any previous editions….The authors’ goals are to provide a complete, authoritative, current, and readable textbook of pharmacology for students in health sciences. Testimony to their success is the widespread use of this work as required textbook for pharmacology courses around the world. This book is used extensively by thousands of medical, pharmacy, podiatry, nursing, and other health professions students to study pharmacology. Likewise, it remains a valuable resource for residents and practicing physicians….I continue to use this book as a required resource for all courses that I teach to medical, nursing, and allied health students. It is authoritative, readable, and supported by numerous learning tools.”–Doody’s Review Service
Organized to reflect the syllabi in Pharmacology courses, Basic & Clinical Pharmacology covers all the important concepts students need to know about the science of pharmacology and its application to clinical practice. It is acknowledged worldwide as the field’s most current, authoritative, and comprehensive textbook. To be as clinically relevant as possible, the book features a strong focus on the choice and use of drugs in patients and the monitoring of their effects. Read More…
Latest News from Pharma Industry:
Pfizer and Kyowa Hakko Kirin to collaborate on immuno-oncology combination study
Pfizer Inc. (NYSE:PFE) and Kyowa Hakko Kirin (Tokyo:4151), have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, an investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell activation, proliferation and survival, with Kyowa Hakko Kirin's anti-CCR4 antibody mogamulizumab,
Transplant drug could boost the power of brain tumor treatments
Every day, organ transplant patients around the world take a drug called rapamycin to keep their immune systems from rejecting their new kidneys and hearts. New research suggests that the same drug could help brain tumor patients by boosting the effect of new immune-based therapies.
New research outlines promising therapies for small cell lung cancer
Two recently published studies by a research team at University Hospitals (UH) Case Medical Center Seidman Cancer Center have the potential to advance treatments for small cell lung cell cancer (SCLC). This aggressive form of lung cancer has seen no treatment advances in 30 years and "is a disease in urgent need of new drug therapies," write the study's authors.
Novo Nordisk establishes new obesity research unit in Seattle
Novo Nordisk has announced that the company will establish a new obesity research unit in Seattle, Washington, in the US. The new unit is a result of Novo Nordisk's increasing focus on treatment of obesity. Its main task will be to identify novel approaches and targets for obesity treatments while increasing the scientific understanding of existing obesity targets.
Discrepancies in access to new cancer drugs revealed
Access to potentially life-extending cancer drugs varies significantly in different regions of the world, two new studies show at the ESMO 2014 Congress in Madrid, Spain. Researchers say the results demonstrate the need for better collaboration between doctors and health authorities on an international scale, to ensure patients have access to the best treatments.